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affect patients months/years post-treatment, when 
centralised follow up in specialised RT clinics is infrequent. A 
feasible cost-effective model to allow remote measurement 
of RT AE is required. eRAPID is a web-based electronic 
patient reporting system including severity linked alerts/self-
management advice 1,2,3. (an RCT assessing feasibility in 
systemic therapy is underway). An eRAPID system for patients 
undergoing radical prostate cancer therapy is being 
developed in St James's Institute of Oncology in Leeds and at 
the Christie Hospital Manchester UK. 
Materials and Methods: To develop eRAPID for RT patients 
we will 1) identify and develop appropriate PROMs(patient-
reported-outcome-measures) to facilitate remote symptom 
reporting, 2) develop and display self-management advice for 
low level problems and determine severity related 
algorithmic treatment responses, 3) map the process of 
current treatment pathways via interviews with patients, key 
professionals and carers, 4) successfully integrate PROM 
questionnaire software (QTool) into existing electronic 
patient records and RT delivery systems to facilitate 'real 
time' data flow. We will ultimately assess the feasibility of 
the eRAPID system in a multi-site trial with prostate and 
other patient groups. 
Results: We have selected appropriate validated PROM AE 
measures from a systematic review of RCT 4. Self-
management advice has been developed for low level AE 
(≤CTCAE grade 2). Using expert consensus methodology we 
have augmented the AE PROM with additional items to 
provide comprehensive coverage of sexual functioning and 
anorectal symptoms. We have successfully mapped the 
patient pathways for radical prostate treatments and 
identified the key health professionals placed to introduce 
the eRAPID system in RT. A pilot of the eRAPID system 
developed for systemic therapy was well received by breast 
cancer patients (n=12) and an RCT with 500 patients in 
systemic therapy is ongoing. 
 
 
Conclusions: We envisage eRAPID will bring benefits for 
patients (better self-management of mild AE, earlier 
detection/treatment of late AE, increased patient 
confidence), benefits for clinicians (improved AE 
documentation, patient management and audit) and benefits 
to the health service (reducing costs from hospital 
contacts/admissions). Ultimately systematic electronic 
collection of treatment related-AE will allow the 
development of predictive models of care and allow 
comparison and evaluation of new RT approaches. 
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Purpose/Objective: This study determined rates of acute 
toxicity in participants with prostate cancer receiving helical 
image guided IMRT on 2 TomoTherapy units. Prescriptions of 
60 Gy in 20 fractions in 4 weeks (cohort A) were compared to 
74 Gy in 37 fractions in 7½ weeks (cohort B). This is a sub-
study of VoxTox, a large research programme, linking daily 
delivered dose during radiotherapy with toxicity. 
Materials and Methods: All participants received radical 
radiotherapy (RT) to the prostate. Of 118 participants, 47 
were in cohort A and 71 in cohort B. Participants were not 
randomised; doses were prescribed using clinical judgement.  
Participants were approached for the study at their pre-
treatment appointment and consent was received prior to 
treatment commencing. A baseline questionnaire was 
completed at consent and acute toxicity questionnaires were 
completed during treatment at 2-week intervals, until 4 
weeks after treatment. 
Baseline and acute toxicity questionnaires were developed by 
the VoxTox research team, and designed so that results could 
be mapped onto validated toxicity scales. This study focussed 
on urinary and bowel function.  
All data were collected directly into an electronic clinical 
report form (eCRF) by a trained healthcare professional. The 
eCRF system proved highly effective, as missing data became 
minimal. 
Results: The two cohorts were balanced at baseline. 
Approximately half the participants experienced grade 1 
urinary issues (51% vs 45%) and the majority had no bowel 
issues (92% vs 89%). Grade 2 or greater (2+) urinary issues 
were seen in 28% vs 27% and bowel issues were seen in 7% vs 
3%. 
During treatment, the rate of toxicity development was 
steeper in cohort A than cohort B, due to the dose 
acceleration from the higher dose per fraction. Urinary 
toxicity was greater at week 2 in cohort A compared with 
cohort B, with grade 2+ toxicity experienced by 37% 
compared with 30%. These rates remained stable for both 
cohorts during the rest of treatment. Bowel toxicity peaked 
towards the end of treatment in both cohorts; rates again 
were higher in cohort A than cohort B, at 25% vs 14%. 
After RT, urological recovery in the 2 cohorts was almost 
identical. At 2 weeks, the rate of grade 2+ toxicity was 13% 
for both. This remained fairly constant: rates were 12% & 11% 
at week 4 after treatment. Bowel recovery however showed a 
difference between cohorts at 2 weeks after RT, with toxicity 
of 20% for cohort A vs 12% for cohort B. This difference 
between the groups had reduced by week 4 and rates were 
7% vs 13% at this point. These data will soon be correlated 
with accumulated dose during the course of treatment (DA). 
Conclusions: This study indicates greater acute urinary 
toxicity in the hypofractionated group, but equivalent rates 
and degree of recovery for both cohorts. Acute bowel toxicity 
was also greater with hypofractionation. The degree of 
recovery was again similar, but took longer for the 
hypofractionated group. These results are comparable to 
those found by the CHHiP prostate RT study, validating our 
methodology.  
   
